Your browser doesn't support javascript.
loading
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou, Caicun; Wang, Ziping; Sun, Yuping; Cao, Lejie; Ma, Zhiyong; Wu, Rong; Yu, Yan; Yao, Wenxiu; Chang, Jianhua; Chen, Jianhua; Zhuang, Wu; Cui, Jiuwei; Chen, Xueqin; Lu, You; Shen, Hong; Wang, Jingru; Li, Peiqi; Qin, Mengmeng; Lu, Dongmei; Yang, Jason.
Afiliação
  • Zhou C; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: caicunzhoudr@163.com.
  • Wang Z; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Sun Y; Department of Oncology, Jinan Central Hospital, Jinan, China; Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Jinan, China.
  • Cao L; Department of Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China.
  • Ma Z; Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Wu R; Department of Oncology, Shengjing Hospital of China Medical University, Huaxiang Branch Hospital, Shenyang, China.
  • Yu Y; Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yao W; Thoracic Oncology, Sichuan Cancer Hospital and Institute, Chengdu, China.
  • Chang J; Department of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China; Department of Oncology, Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Centre, Shenzhen, China.
  • Chen J; Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China.
  • Zhuang W; Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China.
  • Cui J; Pharmacology Base, The First Hospital of Jilin University, Changchun, China.
  • Chen X; Department of Thoracic Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Zhejiang University Cancer Centre, Hangzhou, China.
  • Lu Y; Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Shen H; Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Wang J; Clinical Development, CStone Pharmaceuticals, Suzhou, China.
  • Li P; Clinical Development, CStone Pharmaceuticals, Suzhou, China.
  • Qin M; Clinical Development, CStone Pharmaceuticals, Suzhou, China.
  • Lu D; Clinical Development, CStone Pharmaceuticals, Suzhou, China.
  • Yang J; Clinical Development, CStone Pharmaceuticals, Suzhou, China.
Lancet Oncol ; 23(2): 220-233, 2022 02.
Article em En | MEDLINE | ID: mdl-35038432
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Inibidores de Checkpoint Imunológico / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article